The Present: Non-Invasive Neuromodulation for Headache

Nathaniel M. Schuster, MD Pain and Headache Neurologist Associate Professor UC San Diego Center for Pain Medicine UC San Diego Department of Anesthesiology

Disclosures

- Dr. Schuster has documented that he has served over the past 24 months a consultant for Eli Lilly & Co, Averitas, Lundbeck, and Schedule 1 Therapeutics, as a speaker for Eli Lilly & Co and Averitas, and as an editorial board member for *Pain Medicine, Interventional Pain Medicine, and Annals of Headache Medicine*
- This presentation contains off-label or investigational use of drugs or products

Learning Objectives

- Attendees will learn about <u>5 devices</u> for portable non-invasive neuromodulation
- Attendees will learn about *indications* for these devices
- Attendees will learn about <u>barriers</u> patients may encounter to obtaining these devices (including insurance coverage and out-ofpocket costs)

Portable non-invasive neuromodulation devices

Cefaly	supraorbital peripheral nerve stimulation	migraine	acute and prevention	OTC Cefaly.com	No insurance approval, \$379 x 1 time, Return by 90 days and get money back
gammaCore	vagus peripheral nerve stimulation	migraine and cluster headache	acute and prevention	Rx Gammacore.c om	May cost pt \$199+/month
sTMS mini	occipital cortex transcranial magnetic stimulation	migraine	acute (especially aura) and prevention	Rx Eneura.com	Insurance approval, even with may cost pt \$250/month
Nerivio	arm band remote electrical neuromodulation	migraine	acute	Rx Nerivio.com	\$99 for 12 treatments without insurance Can be \$10+ w/insurance

Population

		Episodic Migraine (<15 headache days/mo or <8 migraine days/mo)	Chronic Migraine (≥15 headache days/mo and ≥ 8 migraine days/mo)
		APAP & NSAIDs ASA/APAP/Caffeine Triptans	?Medication Overuse Gepants D2 Antagonists
<u>Acute/</u> Abortive		D2 Antagonists Frgots	Timolol eye drops
		Gepants Lasmiditan Timolol eye drops	APAP & NSAIDs Triptans Lasmiditan
<u>Ireatments</u>		AEDs (Topiramate esp.) Beta-Blockers/ARBs TCAs/Venlafaxine	OnabotulinumtoxinA CGRPs (mAbs/PO) AEDs (Topiramate esp.)
	<u>Preventive/</u>	CGRPs (mAbs/PO)	Beta-Blockers/ARBs
	<u>Prophylactic</u>	Nemantine Nutraceuticals (Mg, B2) Neuromodulation Lifestyle Treatments	Memantine Nutraceuticals (Mg, B2) Neuromodulation Lifestyle Treatments

Population

		Episodic Migraine (<15 headache days/mo or <8 migraine days/mo)	Chronic Migraine (\geq 15 headache days/mo and \geq 8 migraine days/mo)
Treatments	Acute	APAP & NSAIDs ASA/APAP/Caffeine Triptans D2 Antagonists Ergots Gepants Lasmiditan Timolol eye drops <u>Neuromodulation</u>	 ?Medication Overuse Gepants D2 Antagonists Timolol eye drops <u>Neuromodulation</u> APAP & NSAIDs Triptans Lasmiditan Ergots
	Preventive	AEDs (Topiramate esp.) Beta-Blockers/ARBs TCAs/Venlafaxine CGRPs (mAbs/PO) Memantine Nutraceuticals (Mg, B2) <u>Neuromodulation</u> Lifestyle Treatments	OnabotulinumtoxinA CGRPs (mAbs/PO) AEDs (Topiramate esp.) Beta-Blockers/ARBs TCAs/Venlafaxine Memantine Nutraceuticals (Mg, B2) <u>Neuromodulation</u> Lifestyle Treatments

Adapted from Migdal, Moskatel and Schuster, Pain Medicine, 2021

When to use

- American Headache Society: "Patients who prefer nondrug therapies and those who have failed to respond to, have contraindications to, or poor tolerability with pharmacotherapy may be candidates for neuromodulation"¹
- In tertiary referral clinic practice, most often as a complement to first- and second-line treatments (not monotherapy!)
 - Acute/Abortive and/or Preventive/Prophylactic
 - To avoid medication overuse (rebound) headache
 - Special populations: Adolescents, Pts w/Medical Comorbidities, ?Pregnancy

Supraorbital Nerve Stimulation

Cefaly FDA cleared for:

- Migraine Prevention: 20 min preferably QHS at 60 Hz
- Acute Migraine: 60 min preferably early in migraine attack at 100 Hz
 - Both pulse width 250 μ s, max 16 mA

Evidence

- Prevention: Positive sham-controlled RCT¹
- Acute: Positive sham-controlled RCT²
- In chronic migraine: more effective in patients with intermittent than continuous headache³
- BOLD-fMRI study suggested antinociceptive modulation in the anterior cingulate cortex (ACC)⁴



Single-Pulse TMS



sTMS mini (previously called Spring TMS) FDA cleared for:

- Migraine Prevention: 4 pulses (2 pulses, wait 15 min, 2 pulses) twice daily
- Acute Migraine: 3 pulses at migraine pain onset, can repeat after 15 minutes x 2 if needed

Evidence

- Acute: Positive sham-controlled RCT¹
- Prevention: Positive prospective open-label study²
- Adolescents: Open-label prevention study suggested feasible, well-tolerated³
- Frequency of KCl-induced cortical spreading depression waves reduced in rats treated with spTMS⁴

Vagus nerve stimulation

gammaCore FDA cleared for:

- Acute Migraine: 2 minutes at onset, can repeat after 15 minutes if needed
- Acute Cluster: 2 minutes on, 1 minute off, x 3
- Chronic Cluster Prevention: 2 minutes on, 5 minutes off, x 3, twice a day

Evidence

- Acute Cluster: 2 positive sham-controlled RCTs^{1,2}
- Acute Migraine: Positive sham-controlled RCT³
- Chronic Cluster Prevention: Positive open-label pragmatic RCT⁴
- Vestibular Migraine: Retrospective study suggests helpful⁵
- Decreases release of pro-inflammatory cytokines and chemokines⁶

1. Silberstein et al, Headache 2016 2. Goadsby et al, Cephalalgia 2018, 3. Tassorelli et al, Neurology 2018 4. Gaul et al, Cephalalgia 2016, 5. Beh and Friedman, Neurology 2019 6. Lerman et al, Neuromodulation, 2016.



Remote Electrical Neuromodulation

Nerivio FDA cleared for:

- Acute Migraine: 45 min within 60 min of onset of migraine
- Acute Migraine in Adolescents

Evidence

- Acute Migraine: 2 positive sham-controlled RCTs^{1,2}
- Acute Migraine in Adolescents: Prospective open-label single-arm study³
- Acute Migraine in patients with Chronic Migraine: Prospective open-label single-arm study⁴
- Conditioned Pain Modulation: activates descending inhibition pathways ²

1. Yarnitsky et al, Neurology 2017. 2. Yarnitsky et al, Headache 2019. 3. Hershey et al, Headache3 2020. 4. Grosberg et al, Pain Reports 2021.



Occipital and Trigeminal Neuromodulation

Relivion FDA cleared (not yet commercially available):

• Acute Migraine

Evidence

 Acute Migraine: 1 positive sham-controlled RCT [Abstract Only]¹



1. Tepper SJ, Sharon R. Noninvasive Combined Occipital And Trigeminal Nerve Stimulation For Treatment of Migraine – A Multi-Center, Randomized, Sham-Controlled Pivotal Study. American Headache Society. 2021.

Portable non-invasive neuromodulation devices

Cefaly	supraorbital peripheral nerve stimulation	migraine	acute and prevention	OTC Cefaly.com	No insurance approval, \$379 x 1 time, Return by 90 days and get money back
gammaCore	vagus peripheral nerve stimulation	migraine and cluster headache	acute and prevention	Rx Gammacore .com	May cost \$199+/month
sTMS mini	occipital cortex transcranial magnetic stimulation	migraine	acute (especially aura) and prevention	Rx Eneura.com	Insurance approval, even with may cost \$250/month
Nerivio	arm band remote electrical neuromodulation	migraine	acute	Rx Nerivio.com	\$99 for 12 treatments without insurance Can be \$10+/mo with insurance